04 Oct Drug TARGET REVIEW: Le développement de la thérapie cellulaire et génique se poursuit dans le domaine des indications cardiaques
The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease areas. CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the potential and progress for CGTs in cardiology, where disease-modifying therapies are largely non-existent.
Drug TARGET REVIEW – Ibon Garitaonandia | 2 octobre 2024